RBC L 3.76( 4.30 - 5.90) 10*12/L
Hemoglobin L 122 (135 - 180) g/L
Hematocrit L 0.37 (0.41 - 0.52) L/L

Healthy kidneys produce a hormone called erythropoietin, or EPO, which stimulates the bone marrow to make red blood cells needed to carry oxygen throughout the body. Diseased kidneys don’t make enough EPO, and bone marrow then makes fewer red blood cells.

Креатинин мог подняться из-за повышения дозы ингибиторов?

он провоцировал внезапные проблемы с сердцем

Public Communication - Health Canada Endorsed Important Safety Information on RASILEZ (aliskiren) and RASILEZ HCT (aliskiren/hydrochlorothiazide)

January 23, 2012

Subject: Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ*) or aliskiren/hydrochlorothiazide (RASILEZ HCT*).

Novartis Pharmaceuticals Canada Inc. ("Novartis"), in collaboration with Health Canada, would like to inform you about important new safety information for aliskiren-containing products, RASILEZ* and RASILEZ HCT*, following interim results review from a clinical study ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints). Interim results indicated a higher frequency of non-fatal strokes, serious renal complications, hyperkalemia (high potassium levels in the blood) and hypotension (low blood pressure) in patients treated with aliskiren.

Aliskiren (RASILEZ*) is a medication that helps to reduce hypertension (high blood pressure). It can be used alone or in combination with selected other agents such as thiazide diuretics, angiotensin converting enzyme inhibitors, angiotensin II AT1 receptor blockers or dihydropyridine calcium channel blockers. Aliskiren and hydrochlorothiazide (RASILEZ HCT*) are also indicated to treat hypertension.

Analyses of the ALTITUDE interim results are still ongoing. Until further analyses are available, the treatment of patients with type 2 diabetes taking RASILEZ* or RASILEZ HCT should be revised as early as possible using the following advice:

RASILEZ* and RASILEZ HCT* should not be used with the other classes of medications for the treatment of hypertension called angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) in patients with type 2 diabetes, therefore:
Talk to your doctor if you are taking RASILEZ* or RASILEZ HCT* and if you have type 2 diabetes
Your doctor should not prescribe RASILEZ* or RASILEZ HCT* if you have type 2 diabetes and you are also taking either an ACE inhibitor or ARB
You should NOT stop any of these treatments before discussing with your doctor
Novartis has also sent a letter to all healthcare professionals to inform them of this new safety information. A copy of that letter is available on the Health Canada website.
Call for Reporting
You should report any suspected adverse reactions associated with use of RASILEZ* or RASILEZ HCT* to Health Canada (See below). Adverse reaction should also be reported to Novartis Pharmaceuticals Canada Inc. (See below).

и пообщаться с хирургом и его сестрами

Так что в апреле 17-го пойду под ножъ

А мне 13 марта закрыли фистулу.Тоже был под ножом ))).Сказали не нужна.

Дай Бог